said the transaction will be funded from internal accruals.
For the year ended December 2021, Access Healthcare had revenues of Rs 25 crore and a profit after tax of Rs 9.4 crore. The company has no debt on its books.
Access Healthcare provides pharmaceutical companies marketing and sales solutions in the MENA (Middle East & North Africa) region.
In the UAE market the company supplies products through the Dubai Health Authority. It has market authorizations by the UAE regulatory authorities for various products.
“This acquisition strengthens our presence and market reaching Rs 2,000 crores in revenues, improving our margins over the next couple of years and delivering superior returns for our shareholders,” said Mark Saldanha, promoter and managing director Marksans Pharma.
This deal will enable Marksans to use the front-end sales and access to distributors of Access Healthcare in MENA region to market its products manufactured in India, UK and US.